EP2285818A4 - BELOXEPINE, ITS ENANTIOMERS AND ANALOGUE FOR PAIN TREATMENT - Google Patents

BELOXEPINE, ITS ENANTIOMERS AND ANALOGUE FOR PAIN TREATMENT

Info

Publication number
EP2285818A4
EP2285818A4 EP09712730A EP09712730A EP2285818A4 EP 2285818 A4 EP2285818 A4 EP 2285818A4 EP 09712730 A EP09712730 A EP 09712730A EP 09712730 A EP09712730 A EP 09712730A EP 2285818 A4 EP2285818 A4 EP 2285818A4
Authority
EP
European Patent Office
Prior art keywords
beloxepin
enantiomers
analogs
pain
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09712730A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2285818A2 (en
Inventor
Bourdonnec Bertrand Le
Roland Dolle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adolor Corp
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of EP2285818A2 publication Critical patent/EP2285818A2/en
Publication of EP2285818A4 publication Critical patent/EP2285818A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP09712730A 2008-02-19 2009-02-19 BELOXEPINE, ITS ENANTIOMERS AND ANALOGUE FOR PAIN TREATMENT Withdrawn EP2285818A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2991508P 2008-02-19 2008-02-19
US2991608P 2008-02-19 2008-02-19
US2991308P 2008-02-19 2008-02-19
US5092108P 2008-05-06 2008-05-06
PCT/US2009/034461 WO2009105507A2 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Publications (2)

Publication Number Publication Date
EP2285818A2 EP2285818A2 (en) 2011-02-23
EP2285818A4 true EP2285818A4 (en) 2011-08-17

Family

ID=40986169

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09712730A Withdrawn EP2285818A4 (en) 2008-02-19 2009-02-19 BELOXEPINE, ITS ENANTIOMERS AND ANALOGUE FOR PAIN TREATMENT

Country Status (11)

Country Link
EP (1) EP2285818A4 (hr)
JP (1) JP2011512414A (hr)
KR (1) KR20100137473A (hr)
CN (1) CN102007139A (hr)
AU (1) AU2009215541A1 (hr)
BR (1) BRPI0908098A2 (hr)
CA (1) CA2715192A1 (hr)
IL (1) IL207668A0 (hr)
MX (1) MX2010009110A (hr)
NZ (2) NZ594937A (hr)
WO (1) WO2009105507A2 (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
WO2016138138A1 (en) * 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62754B1 (en) 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
GB0019950D0 (en) 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
AU2003283656A1 (en) * 2002-12-11 2004-06-30 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
MXPA06005019A (es) * 2003-11-03 2006-07-06 Warner Lambert Co Nuevos inhibidores de la recaptacion de norpinefrina para el tratamiento de transtornos del sistema nervioso central.
CA2588595A1 (en) * 2004-12-13 2006-06-22 Arena Pharmaceuticals, Inc. N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
EA013595B1 (ru) * 2005-01-27 2010-06-30 Янссен Фармацевтика Н.В. Гетероциклические, тетрациклические производные гидрофурана в качестве ингибиторов 5htв терапии расстройств цнс
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
JP2009510095A (ja) * 2005-09-29 2009-03-12 ワイス モノアミン再取り込みにより改善する症状の処置において使用するためのベンゾチアジアゾリフェニルアルキルアミン誘導体
US7557088B2 (en) * 2006-03-28 2009-07-07 Neopro Labs, Llc Methods and compositions for treating conditions
GB0608655D0 (en) * 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUIGT G S F ET AL: "Antidepressant characteristics of Org 3770, Org 4428 and Org 9768 on rat sleep", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, vol. 183, no. 4, 4 July 1990 (1990-07-04), pages 1467 - 1468, XP023838768, ISSN: 0014-2999, [retrieved on 19900704], DOI: 10.1016/0014-2999(90)94611-Z *

Also Published As

Publication number Publication date
CN102007139A (zh) 2011-04-06
AU2009215541A1 (en) 2009-08-27
JP2011512414A (ja) 2011-04-21
MX2010009110A (es) 2010-11-30
CA2715192A1 (en) 2009-08-27
WO2009105507A2 (en) 2009-08-27
NZ594937A (en) 2013-03-28
NZ587896A (en) 2011-09-30
WO2009105507A3 (en) 2010-01-14
BRPI0908098A2 (pt) 2015-08-18
KR20100137473A (ko) 2010-12-30
IL207668A0 (en) 2010-12-30
EP2285818A2 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
HUS1600057I1 (hu) Kezelési eljárások ammónia-megkötõ hatóanyag alkalmazásával
HK1255227A1 (zh) 疼痛治療
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
GB2483419B (en) Formulations for the treatment of deep tissue pain
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
EP2164494A4 (en) Methods of Treatment
GB0723100D0 (en) Treatment of HFnEF
SI2278962T1 (sl) Postopki za zdravljenje dermatoloških motenj
GB0814043D0 (en) The treatment of skin disorders
GB0809319D0 (en) The treatment of puritus
GB0720136D0 (en) Treatment of blood disorded
GB0700969D0 (en) Methods of treatment
IL207753A0 (en) Substituted 4-aminocyclohexane derivatives for the treatment of pain
SI2330892T1 (sl) Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100906

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

A4 Supplementary search report drawn up and despatched

Effective date: 20110715

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 17/08 20060101AFI20110711BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154866

Country of ref document: HK

17Q First examination report despatched

Effective date: 20120625

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140416

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154866

Country of ref document: HK